Revolution Medicines

The firm’s core approach relies on a proprietary platform for designing tri-complex inhibitors that target the active, GTP-bound form of RAS proteins. This mechanism of action is distinct from earlier attempts that targeted the inactive state. The goal is to suppress oncogenic signaling pathways that drive tumor growth in RAS-addicted cancers.

The pipeline is directed primarily at advanced solid tumors harboring RAS mutations. Published clinical programs focus on non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. The lead candidate, daraxonrasib, targets multiple RAS variants, while earlier programs were designed for specific mutations like KRAS G12C.

The company is publicly traded on the Nasdaq Global Select Market under the symbol RVMD. Before its public listing, it raised capital through a series of private venture rounds, drawing investment from specialized biotech funds. Liquidity in the public equity markets is the primary mechanism for outside allocators to hold a stake in the firm.

No. It is structured as a standalone biotechnology corporation with a standard public-company governance framework. It does not serve as a capital vehicle for a private family wealth origin and does not manage third-party capital in a fund structure; its balance sheet directly funds internal drug development programs and operations.

The lead clinical candidate is daraxonrasib (RMC-6236), an oral RAS(ON) multi-selective inhibitor. The molecule is being evaluated in monotherapy and combination trials for advanced solid tumors, representing the firm’s most mature value driver as research translates into potential regulatory outcomes.